Regulatory & Legal

A new financial tool gives cannabis operators crucial liquidity, while a major partnership between Safe Harbor and Canopy HR reshapes the industry's banking landscape.

Granted a tight deadline by Nasdaq, Triller Group must fix its finances and failing stock price or face delisting. Is its hybrid social media-fintech model viable?

The fashion giant beat earnings and initiated a dividend, but declining sales and consumer uncertainty reveal a complex picture for the apparel industry.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.

A leading stainless steel giant partners with a spiritual organization to tackle addiction, signaling a strategic shift in corporate social responsibility.

Independent 2025 endpoint security tests expose the top performers and true costs, offering CISOs a clear guide to navigating a complex market.

A top global forum warns of politicized trade and tech divides. How will this impact pharma supply chains, AI in medicine, and market access?

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

Paychex is betting on AI to transform HR, from automating payroll to mining unstructured data. Is this the future of workforce management?

After teetering on the edge of delisting, cbdMD has regained NYSE compliance. A deep dive into the strategic financial moves that saved its market standing.

A key regulatory filing reveals First Trust Advisors' major stake in NCC Group, fueling speculation as the UK cybersecurity firm weighs a potential sale.

Emergency rooms are failing kids in crisis. See how one hospital is partnering with community experts to build a faster, more effective path to healing.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

As AI-driven deepfakes surge, a 5-year-old film reveals why media literacy is the most critical, yet overlooked, infrastructure for our smart cities.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

Quantum computers will soon break today's encryption. A new security standard is here, but are automakers moving fast enough to prevent a systemic failure?

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.